A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification

Oktay, Kaan; Santaliz-Casiano, Ashlie; Patel, Meera; Marino, Natascia; Storniolo, Anna Maria; Torun, Hamdi; Açar, Burak; Madak-Erdoğan, Zeynep

doi:10.1007/s12672-019-00372-3

Cited by 20 publications

(18 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the specific case of breast cancer, ctDNA has been correlated to patients’ relapse after surgery and adjuvant treatment, predicting it one to two years before the clinical evidence of the metastatic disease, also correlating with the disease burden 72 . Moreover, ctDNA has been shown to correlate to tumor dynamics in breast cancer patients undergoing surgical or medical therapy 73 , and to be a valuable screening methodology for the selection of breast cancer patients for a specific target drug treatment 74 , 75 .…”

Section: Liquid Biopsies For Breast Cancermentioning

confidence: 99%

Liquid biopsies and cancer omics

et al. 2020

View full text Add to dashboard Cite

The development of the sequencing technologies allowed the generation of huge amounts of molecular data from a single cancer specimen, allowing the clinical oncology to enter the era of the precision medicine. This massive amount of data is highlighting new details on cancer pathogenesis but still relies on tissue biopsies, which are unable to capture the dynamic nature of cancer through its evolution. This assumption led to the exploration of non-tissue sources of tumoral material opening the field of liquid biopsies. Blood, together with body fluids such as urines, or stool, from cancer patients, are analyzed applying the techniques used for the generation of omics data. With blood, this approach would allow to take into account tumor heterogeneity (since the circulating components such as CTCs, ctDNA, or ECVs derive from each cancer clone) in a time dependent manner, resulting in a somehow “real-time” understanding of cancer evolution. Liquid biopsies are beginning nowdays to be applied in many cancer contexts and are at the basis of many clinical trials in oncology.

show abstract

Section: Liquid Biopsies For Breast Cancermentioning

confidence: 99%

Liquid biopsies and cancer omics

et al. 2020

View full text Add to dashboard Cite

show abstract

“…SCF is the most important molecule for MC development, survival and activation. A recent proteomic analysis of plasma samples found lower levels of SCF in women that later developed BrC than in those that remained healthy, supporting SCF as a circulating biomarker, and indirectly suggesting an enhanced tumor controlling mechanism of SCF-activated MCs [55]. On the other hand, TGF-β1 relevance in cancer stems from its association with the epithelial to mesenchymal transition (EMT) [56], an embryonic program in which cells lose expression of adherent proteins and gain expression of movement proteins.…”

Section: Discussionmentioning

confidence: 95%

An In Vitro Model of Mast Cell Recruitment and Activation by Breast Cancer Cells Supports Anti-Tumoral Responses

Aponte-López

Enciso

Muñoz-Cruz

et al. 2020

IJMS

View full text Add to dashboard Cite

Breast cancer (BrC) affects millions of women yearly. Mast cells (MCs) are common components of breast tumors with documented agonistic and antagonistic roles in tumor progression. Understanding the participation of MCs in BrC may lead to new therapies to control tumor growth. In this study, we looked into mechanistic models of MC responses triggered by BrC cells (BrCC), assessing both early degranulation and late transcriptional activities. We used aggressive and non-aggressive BrCC to model the progressive staging of the disease over HMC1 and LAD-2 human MC lines. We found that both MC lines were chemoattracted by all BrCC, but their activation was preferentially induced by aggressive lines, finding differences in their active transcriptional programs, both at basal level and after stimulation. Among those genes with altered expression were down-regulated SPP1, PDCD1, IL17A and TGFB1 and up-regulated KITLG and IFNG. A low expression of SPP1 and a high expression of KITLG and IFNG were associated with increased overall survival of BrC patients from public databases. The set of altered genes is more often associated with tumor stromas enriched with anti-tumoral signals, suggesting that MCs may participate in tumor control.

show abstract

“…While currently, selection of ET for women with advanced ER+ breast cancer is based on IHC assays of ER, PgR, and HER2, there are many emerging methods based on more extensive genomic, transcriptomic, proteomic, metabolomic, and other information-rich characterizations of biopsy samples [21][22][23] . These "-omic" analyses, as well as those based on specific candidate genes of interest on tumor tissue biopsies largely remain investigational.…”

Section: Discussionmentioning

confidence: 99%

Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy

Dehdashti

Cynthia

et al. 2021

Nat Commun

View full text Add to dashboard Cite

Estrogen receptor (ER) testing of breast cancer imperfectly predicts response to endocrine therapy (ET). We hypothesize that a brief estradiol challenge will increase tumor progesterone receptor (PgR) levels only in tumors with functional ER. In this prospective, phase 2, single-center, single-arm trial (NCT02455453), we report the association of response to ET with change in tumor uptake of the progestin analog, 21-[18F]fluorofuranylnorprogesterone (FFNP), before and after a one-day estradiol challenge. In 43 postmenopausal women with advanced ER+ breast cancer, we show a post-challenge increase in tumor FFNP uptake only in 28 subjects with clinical benefit from ET (responders), but not in 15 without clinical benefit (nonresponders) (p < 0.0001), indicating 100% sensitivity and specificity. We further show significantly longer survival (p < 0.0001) in the responding subjects. Our results demonstrate that change in tumor FFNP uptake after estradiol challenge is highly predictive of response to ET in women with ER+ breast cancer.

show abstract

A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification

Abstract: Man c ip Click he e o acce /do nload;Man c ip ;Cance find HOCA R1 4.doc Click he e o ie linked Refe ence identification of breast cancer risk and hence decreased mortality. Our findings provide the knowledge basis needed to proceed in this direction.

Cited by 20 publications

References 48 publications

Liquid biopsies and cancer omics

Liquid biopsies and cancer omics

An In Vitro Model of Mast Cell Recruitment and Activation by Breast Cancer Cells Supports Anti-Tumoral Responses

Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy

Contact Info

Product

Resources

About